Mavacamten - CAMZYOS capsules | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Review first - source-specific qualification

Before use: Mavacamten - CAMZYOS capsules

PK observations are not a renal dosing ladder; the source groups overlap at 30.

Before applying: Review current full CAMZYOS monitoring and interaction requirements; do not select a dose from these PK rows.

Evidence for this qualification

Source-specific interpretation; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Mavacamten - CAMZYOS capsules

Product / population: Adult symptomatic obstructive hypertrophic cardiomyopathy. Renal pharmacokinetics only.
Renal measure: Indexed eGFR, mL/min/1.73 m2

Renal guidance and important limits

Limits that apply to these rows

The printed groups overlap at exactly 30; no boundary is corrected or dose inferred.

Heart-failure precautions, echocardiographic LVEF monitoring and CYP-related interaction rules govern use. Do not initiate when LVEF is below 55%; interrupt below 50% per the selected label.

CAMZYOS - renal pharmacokinetic evidence
eGFR, mL/min/1.73 m2	Source-specific dose / instruction
60-89 and 30-59	No clinically important PK differences observed
15-30	Effect unknown
<15 including dialysis	Effect unknown

Read the retained text before reformatting

CAMZYOS - renal pharmacokinetic evidence

eGFR, mL/min/1.73 m2	Source-specific dose / instruction
60-89 and 30-59	No clinically important PK differences observed
15-30	Effect unknown
<15 including dialysis	Effect unknown

The printed groups overlap at exactly 30; no boundary is corrected or dose inferred.

Heart-failure precautions, echocardiographic LVEF monitoring and CYP-related interaction rules govern use. Do not initiate when LVEF is below 55%; interrupt below 50% per the selected label.

Source revision: 4/2025 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=669c936b-3ee6-4e36-8a22-79dd11b1255b

Scope: Selected source sections stored locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Mavacamten - CAMZYOS capsules

Authored v6.3; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Mavacamten - CAMZYOS capsules

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Before using this finding

Review current full CAMZYOS monitoring and interaction requirements; do not select a dose from these PK rows.

Dialysis evidence: No dialysis regimen established in selected content

Adult symptomatic obstructive hypertrophic cardiomyopathy. Renal pharmacokinetics only.

Renal method: Indexed eGFR, mL/min/1.73 m2
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope and renal guidance

Before use: Mavacamten - CAMZYOS capsules

PK observations are not a renal dosing ladder; the source groups overlap at 30.

How to use this: Review current full CAMZYOS monitoring and interaction requirements; do not select a dose from these PK rows.

Mavacamten - CAMZYOS capsules

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Official source

Mavacamten - CAMZYOS capsules

Adult symptomatic obstructive hypertrophic cardiomyopathy. Renal pharmacokinetics only.

Method: Indexed eGFR, mL/min/1.73 m2

Renal guidance and important limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope Mavacamten - CAMZYOS capsules

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=669c936b-3ee6-4e36-8a22-79dd11b1255b

Exact product and population

Adult symptomatic obstructive hypertrophic cardiomyopathy. Renal pharmacokinetics only.

RDM63-SCOPE-mavacamten · Source section: Selected source product scopeRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

Mavacamten - CAMZYOS capsules

Open original reference

Open / share this exact local source

DailyMed / NLM exact product labeling · Adult symptomatic obstructive hypertrophic cardiomyopathy. Renal pharmacokinetics only.

Renal method: Indexed eGFR, mL/min/1.73 m2
Source date: 4/2025
Retrieved: 2026-09-10

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Before using this finding

Review current full CAMZYOS monitoring and interaction requirements; do not select a dose from these PK rows.

Dialysis evidence: No dialysis regimen established in selected content

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

The printed groups overlap at exactly 30; no boundary is corrected or dose inferred.

Heart-failure precautions, echocardiographic LVEF monitoring and CYP-related interaction rules govern use. Do not initiate when LVEF is below 55%; interrupt below 50% per the selected label.

CAMZYOS - renal pharmacokinetic evidence
eGFR, mL/min/1.73 m2	Source-specific dose / instruction
60-89 and 30-59	No clinically important PK differences observed
15-30	Effect unknown
<15 including dialysis	Effect unknown

Read the retained text before reformatting

CAMZYOS - renal pharmacokinetic evidence

eGFR, mL/min/1.73 m2	Source-specific dose / instruction
60-89 and 30-59	No clinically important PK differences observed
15-30	Effect unknown
<15 including dialysis	Effect unknown

The printed groups overlap at exactly 30; no boundary is corrected or dose inferred.

Heart-failure precautions, echocardiographic LVEF monitoring and CYP-related interaction rules govern use. Do not initiate when LVEF is below 55%; interrupt below 50% per the selected label.

RDM63-official-mavacamten-d7c18e961d-C1 · Source locator: Clinical pharmacology 12.3; boxed warning and dosing safeguards

Source-specific limits

The printed groups overlap at exactly 30; no boundary is corrected or dose inferred.

Heart-failure precautions, echocardiographic LVEF monitoring and CYP-related interaction rules govern use. Do not initiate when LVEF is below 55%; interrupt below 50% per the selected label.

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=669c936b-3ee6-4e36-8a22-79dd11b1255b
Retrieved: 2026-09-10
Exact label title: Mavacamten - CAMZYOS capsules
DailyMed Set ID: 669c936b-3ee6-4e36-8a22-79dd11b1255b
Label revision: 4/2025
Renal-function method: Indexed eGFR, mL/min/1.73 m2
Source date/version: 4/2025
Hash meaning: Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256: 3c0ec8c8d128c346cbbb100c64cd082025e7d405379c3819ce88a4105cbe6fec

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=669c936b-3ee6-4e36-8a22-79dd11b1255b
Source retrieval: 2026-09-10. This is not the source publication or label revision date.
Original source type: rxlist summary
Local text SHA-256: faa40b0ac18817cf94c52cb9bb0254c8c3a6025fe6ac4e87455bf15fada96d10
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report